Evidence map›Paper›PMID 19835996›Full record

ArticleInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2010

Amino acid and structural variability of Yersinia pestis LcrV protein.

Andrey P Anisimov, Svetlana V Dentovskaya, Evgeniy A Panfertsev, Tat'yana E Svetoch, Pavel Kh Kopylov, Brent W Segelke, Adam Zemla, Maxim V Telepnev, Vladimir L Motin

Abstract read
In one paragraph

Article in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Novel Bivalent mRNA-LNP Vaccine for Highly Effective Protection against Pneumonic Plague.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Zoonoses (Shannon, Ireland) · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Biomolecules · 2020
    Review
  16. Article
  17. Review
  18. Polymorphism in theFrontiers in immunology · 2019
    Article
  19. Article
  20. Identification of New Virulence Factors and Vaccine Candidates forFrontiers in cellular and infection microbiology · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Andrey P AnisimovState Research Center for Applied Microbiology and Biotechnology, 142279 Obolensk, Moscow Region, Russia. anisimov@obolensk.org
Svetlana V Dentovskaya
Evgeniy A Panfertsev
Tat'yana E Svetoch
Pavel Kh Kopylov
Brent W Segelke
Adam Zemla
Maxim V Telepnev
Vladimir L Motin
State Research Center for Applied Microbiology and Biotechnology · RULawrence Livermore National Laboratory · USThe University of Texas Medical Branch at Galveston · US

Funding

Development, Production and Evaluation of a Multivalent Adenoviral Plague VaccineR43AI071634 · NIAID · NORWELL, INC. · PI LENTZ, CHRIS · 2008 to 2009
$532k
NIAID NIH HHS 1R43 AI71634-01A2NIAID NIH HHS R43 AI071634
6 · The paper itself

Abstract

The LcrV protein is a multifunctional virulence factor and protective antigen of the plague bacterium and is generally conserved between the epidemic strains of Yersinia pestis. We investigated the diversity in the LcrV sequences among non-epidemic Y. pestis strains which have a limited virulence in selected animal models and for humans. Sequencing of lcrV genes from 19 Y. pestis strains belonging to different phylogenetic groups (subspecies) showed that the LcrV proteins possess four major variable hotspots at positions 18, 72, 273, and 324-326. These major variations, together with other minor substitutions in amino acid sequences, allowed us to classify the LcrV alleles into five sequence types (A-E). We observed that the strains of different Y. pestis "subspecies" can have the same type of LcrV, including that conserved in epidemic strains, and different types of LcrV can exist within the same natural plague focus. Therefore, the phenomenon of "selective virulence" characteristic of the strains of the microtus biovar is unlikely to be the result of polymorphism of the V antigen. The LcrV polymorphisms were structurally analyzed by comparing the modeled structures of LcrV from all available strains. All changes except one occurred either in flexible regions or on the surface of the protein, but local chemical properties (i.e. those of a hydrophobic, hydrophilic, amphipathic, or charged nature) were conserved across all of the strains. Polymorphisms in flexible and surface regions are likely subject to less selective pressure, and have a limited impact on the structure. In contrast, the substitution of tryptophan at position 113 with either glutamic acid or glycine likely has a serious influence on the regional structure of the protein, and these mutations might have an effect on the function of LcrV. The polymorphisms at positions 18, 72 and 273 were accountable for differences in the oligomerization of LcrV.

Indexed as

Amino AcidsAmino Acid SequenceAmino Acid SubstitutionAntigens, BacterialBacterial ProteinsGenes, BacterialLysineModels, MolecularMolecular Sequence DataPore Forming Cytotoxic ProteinsSequence Homology, Amino AcidVirulence FactorsYersinia pestisAmino AcidsAntigens, BacterialBacterial ProteinsLcrV protein, YersiniaLysinePore Forming Cytotoxic ProteinsVirulence Factors

Identifiers

PMID19835996
PMCPMC2818281
OpenAlexW2049311842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.